Diaceutics PLC Presenting at Canaccord Genuity Growth Conference

RNS Number : 0248Z

Diaceutics PLC

05 August 2024

 

Diaceutics Presenting at Canaccord Genuity 44th Annual Growth Conference

​

Belfast and London, 5 August 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry today announces that management will attend and present at the Canaccord Genuity 44^th Annual Growth Conference taking place on August 13-15, 2024 in Boston, MA.

The Conference brings together investors from around the world with some of the best and most promising growth companies in Canaccord's core sectors - Technology, Healthcare, Digital & Tech-Enabled Health, Sustainability, Industrials, and Consumer & Retail. For more information please click here. 

Enquiries: 

 

Diaceutics PLC
Ryan Keeling, Chief Executive Officer   Nick Roberts, Chief Financial Officer	Tel: [phone] [e-mail]
Stifel Nicolaus Europe Limited (Nomad & Broker)	Tel: [phone]
Ben Maddison, Nick Harland, Kate Hanshaw
Alma Strategic Communications	Tel: [phone]
Caroline Forde, Kinvara Verdon	[e-mail]

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCSSEFFEELSESA